|
| | SB1987 Enrolled | | LRB103 25792 RLC 57149 b |
|
|
1 | | AN ACT concerning criminal law.
|
2 | | Be it enacted by the People of the State of Illinois,
|
3 | | represented in the General Assembly:
|
4 | | Section 5. The Illinois Controlled Substances Act is |
5 | | amended by changing Section 204 as follows: |
6 | | (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204) |
7 | | Sec. 204. (a) The controlled substances listed in this |
8 | | Section are
included in Schedule I. |
9 | | (b) Unless specifically excepted or unless listed in |
10 | | another
schedule, any of the following opiates, including |
11 | | their isomers,
esters, ethers, salts, and salts of isomers, |
12 | | esters, and ethers,
whenever the existence of such isomers, |
13 | | esters, ethers and salts is
possible within the specific |
14 | | chemical designation: |
15 | | (1) Acetylmethadol; |
16 | | (1.1) Acetyl-alpha-methylfentanyl |
17 | | (N-[1-(1-methyl-2-phenethyl)-
|
18 | | 4-piperidinyl]-N-phenylacetamide); |
19 | | (2) Allylprodine; |
20 | | (3) Alphacetylmethadol, except
|
21 | | levo-alphacetylmethadol (also known as levo-alpha-
|
22 | | acetylmethadol, levomethadyl acetate, or LAAM); |
23 | | (4) Alphameprodine; |
|
| | SB1987 Enrolled | - 2 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (5) Alphamethadol; |
2 | | (6) Alpha-methylfentanyl
|
3 | | (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
|
4 | | propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
|
5 | | propanilido) piperidine; |
6 | | (6.1) Alpha-methylthiofentanyl
|
7 | | (N-[1-methyl-2-(2-thienyl)ethyl-
|
8 | | 4-piperidinyl]-N-phenylpropanamide); |
9 | | (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP); |
10 | | (7.1) PEPAP
|
11 | | (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine); |
12 | | (8) Benzethidine; |
13 | | (9) Betacetylmethadol; |
14 | | (9.1) Beta-hydroxyfentanyl
|
15 | | (N-[1-(2-hydroxy-2-phenethyl)-
|
16 | | 4-piperidinyl]-N-phenylpropanamide); |
17 | | (10) Betameprodine; |
18 | | (11) Betamethadol; |
19 | | (12) Betaprodine; |
20 | | (13) Clonitazene; |
21 | | (14) Dextromoramide; |
22 | | (15) Diampromide; |
23 | | (16) Diethylthiambutene; |
24 | | (17) Difenoxin; |
25 | | (18) Dimenoxadol; |
26 | | (19) Dimepheptanol; |
|
| | SB1987 Enrolled | - 3 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (20) Dimethylthiambutene; |
2 | | (21) Dioxaphetylbutyrate; |
3 | | (22) Dipipanone; |
4 | | (23) Ethylmethylthiambutene; |
5 | | (24) Etonitazene; |
6 | | (25) Etoxeridine; |
7 | | (26) Furethidine; |
8 | | (27) Hydroxpethidine; |
9 | | (28) Ketobemidone; |
10 | | (29) Levomoramide; |
11 | | (30) Levophenacylmorphan; |
12 | | (31) 3-Methylfentanyl
|
13 | | (N-[3-methyl-1-(2-phenylethyl)-
|
14 | | 4-piperidyl]-N-phenylpropanamide); |
15 | | (31.1) 3-Methylthiofentanyl
|
16 | | (N-[(3-methyl-1-(2-thienyl)ethyl-
|
17 | | 4-piperidinyl]-N-phenylpropanamide); |
18 | | (32) Morpheridine; |
19 | | (33) Noracymethadol; |
20 | | (34) Norlevorphanol; |
21 | | (35) Normethadone; |
22 | | (36) Norpipanone; |
23 | | (36.1) Para-fluorofentanyl
|
24 | | (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
|
25 | | 4-piperidinyl]propanamide); |
26 | | (37) Phenadoxone; |
|
| | SB1987 Enrolled | - 4 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (38) Phenampromide; |
2 | | (39) Phenomorphan; |
3 | | (40) Phenoperidine; |
4 | | (41) Piritramide; |
5 | | (42) Proheptazine; |
6 | | (43) Properidine; |
7 | | (44) Propiram; |
8 | | (45) Racemoramide; |
9 | | (45.1) Thiofentanyl
|
10 | | (N-phenyl-N-[1-(2-thienyl)ethyl-
|
11 | | 4-piperidinyl]-propanamide); |
12 | | (46) Tilidine; |
13 | | (47) Trimeperidine; |
14 | | (48) Beta-hydroxy-3-methylfentanyl (other name:
|
15 | | N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
|
16 | | N-phenylpropanamide); |
17 | | (49) Furanyl fentanyl (FU-F); |
18 | | (50) Butyryl fentanyl; |
19 | | (51) Valeryl fentanyl; |
20 | | (52) Acetyl fentanyl; |
21 | | (53) Beta-hydroxy-thiofentanyl; |
22 | | (54) 3,4-dichloro-N-[2-
|
23 | | (dimethylamino)cyclohexyl]-N-
|
24 | | methylbenzamide (U-47700); |
25 | | (55) 4-chloro-N-[1-[2-
|
26 | | (4-nitrophenyl)ethyl]-2-piperidinylidene]-
|
|
| | SB1987 Enrolled | - 5 - | LRB103 25792 RLC 57149 b |
|
|
1 | | benzenesulfonamide (W-18); |
2 | | (56) 4-chloro-N-[1-(2-phenylethyl)
|
3 | | -2-piperidinylidene]-benzenesulfonamide (W-15); |
4 | | (57) acrylfentanyl (acryloylfentanyl). |
5 | | (c) Unless specifically excepted or unless listed in |
6 | | another
schedule, any of the following opium derivatives, its |
7 | | salts, isomers
and salts of isomers, whenever the existence of |
8 | | such salts, isomers and
salts of isomers is possible within |
9 | | the specific chemical designation: |
10 | | (1) Acetorphine; |
11 | | (2) Acetyldihydrocodeine; |
12 | | (3) Benzylmorphine; |
13 | | (4) Codeine methylbromide; |
14 | | (5) Codeine-N-Oxide; |
15 | | (6) Cyprenorphine; |
16 | | (7) Desomorphine; |
17 | | (8) Diacetyldihydromorphine (Dihydroheroin); |
18 | | (9) Dihydromorphine; |
19 | | (10) Drotebanol; |
20 | | (11) Etorphine (except hydrochloride salt); |
21 | | (12) Heroin; |
22 | | (13) Hydromorphinol; |
23 | | (14) Methyldesorphine; |
24 | | (15) Methyldihydromorphine; |
25 | | (16) Morphine methylbromide; |
26 | | (17) Morphine methylsulfonate; |
|
| | SB1987 Enrolled | - 6 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (18) Morphine-N-Oxide; |
2 | | (19) Myrophine; |
3 | | (20) Nicocodeine; |
4 | | (21) Nicomorphine; |
5 | | (22) Normorphine; |
6 | | (23) Pholcodine; |
7 | | (24) Thebacon. |
8 | | (d) Unless specifically excepted or unless listed in |
9 | | another
schedule, any material, compound, mixture, or |
10 | | preparation which contains
any quantity of the following |
11 | | hallucinogenic substances, or which
contains any of its salts, |
12 | | isomers and salts of isomers, whenever the
existence of such |
13 | | salts, isomers, and salts of isomers is possible
within the |
14 | | specific chemical designation (for the purposes of this
|
15 | | paragraph only, the term "isomer" includes the optical, |
16 | | position and
geometric isomers): |
17 | | (1) 3,4-methylenedioxyamphetamine
|
18 | | (alpha-methyl,3,4-methylenedioxyphenethylamine,
|
19 | | methylenedioxyamphetamine, MDA); |
20 | | (1.1) Alpha-ethyltryptamine
|
21 | | (some trade or other names: etryptamine;
|
22 | | MONASE; alpha-ethyl-1H-indole-3-ethanamine;
|
23 | | 3-(2-aminobutyl)indole; a-ET; and AET); |
24 | | (2) 3,4-methylenedioxymethamphetamine (MDMA); |
25 | | (2.1) 3,4-methylenedioxy-N-ethylamphetamine
|
26 | | (also known as: N-ethyl-alpha-methyl-
|
|
| | SB1987 Enrolled | - 7 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
|
2 | | and MDEA); |
3 | | (2.2) N-Benzylpiperazine (BZP); |
4 | | (2.2-1) Trifluoromethylphenylpiperazine (TFMPP); |
5 | | (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA); |
6 | | (4) 3,4,5-trimethoxyamphetamine (TMA); |
7 | | (5) (Blank); |
8 | | (6) Diethyltryptamine (DET); |
9 | | (7) Dimethyltryptamine (DMT); |
10 | | (7.1) 5-Methoxy-diallyltryptamine; |
11 | | (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP); |
12 | | (9) Ibogaine (some trade and other names:
|
13 | | 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
|
14 | | 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
|
15 | | indole; Tabernanthe iboga); |
16 | | (10) Lysergic acid diethylamide; |
17 | | (10.1) Salvinorin A; |
18 | | (10.5) Salvia divinorum (meaning all parts of the |
19 | | plant presently classified
botanically as Salvia |
20 | | divinorum, whether growing or not, the
seeds thereof, any |
21 | | extract from any part of that plant, and every compound,
|
22 | | manufacture, salts, isomers, and salts of
isomers whenever |
23 | | the existence of such salts, isomers, and salts of
isomers |
24 | | is possible within the specific chemical designation, |
25 | | derivative, mixture, or preparation of that plant, its
|
26 | | seeds or extracts);
|
|
| | SB1987 Enrolled | - 8 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (11) 3,4,5-trimethoxyphenethylamine (Mescaline); |
2 | | (12) Peyote (meaning all parts of the plant presently |
3 | | classified
botanically as Lophophora williamsii
Lemaire, |
4 | | whether growing or not, the
seeds thereof, any extract |
5 | | from any part of that plant, and every compound,
|
6 | | manufacture, salts, derivative, mixture, or preparation of |
7 | | that plant, its
seeds or extracts); |
8 | | (13) N-ethyl-3-piperidyl benzilate (JB 318); |
9 | | (14) N-methyl-3-piperidyl benzilate; |
10 | | (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
|
11 | | (also known as N-hydroxy-alpha-methyl-
|
12 | | 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA); |
13 | | (15) Parahexyl; some trade or other names:
|
14 | | 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
|
15 | | dibenzo (b,d) pyran; Synhexyl; |
16 | | (16) Psilocybin; |
17 | | (17) Psilocyn; |
18 | | (18) Alpha-methyltryptamine (AMT); |
19 | | (19) 2,5-dimethoxyamphetamine
|
20 | | (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA); |
21 | | (20) 4-bromo-2,5-dimethoxyamphetamine
|
22 | | (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
|
23 | | 4-bromo-2,5-DMA); |
24 | | (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
|
25 | | Some trade or other names: 2-(4-bromo-
|
26 | | 2,5-dimethoxyphenyl)-1-aminoethane;
|
|
| | SB1987 Enrolled | - 9 - | LRB103 25792 RLC 57149 b |
|
|
1 | | alpha-desmethyl DOB, 2CB, Nexus; |
2 | | (21) 4-methoxyamphetamine
|
3 | | (4-methoxy-alpha-methylphenethylamine;
|
4 | | paramethoxyamphetamine; PMA); |
5 | | (22) (Blank); |
6 | | (23) Ethylamine analog of phencyclidine.
|
7 | | Some trade or other names:
|
8 | | N-ethyl-1-phenylcyclohexylamine,
|
9 | | (1-phenylcyclohexyl) ethylamine,
|
10 | | N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE; |
11 | | (24) Pyrrolidine analog of phencyclidine. Some trade |
12 | | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, |
13 | | PHP; |
14 | | (25) 5-methoxy-3,4-methylenedioxy-amphetamine; |
15 | | (26) 2,5-dimethoxy-4-ethylamphetamine
|
16 | | (another name: DOET); |
17 | | (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
18 | | (another name: TCPy); |
19 | | (28) (Blank); |
20 | | (29) Thiophene analog of phencyclidine (some trade
|
21 | | or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
|
22 | | 2-thienyl analog of phencyclidine; TPCP; TCP); |
23 | | (29.1) Benzothiophene analog of phencyclidine. Some |
24 | | trade or other names: BTCP or benocyclidine; |
25 | | (29.2) 3-Methoxyphencyclidine (3-MeO-PCP); |
26 | | (30) Bufotenine (some trade or other names:
|
|
| | SB1987 Enrolled | - 10 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
|
2 | | 3-(2-dimethylaminoethyl)-5-indolol;
|
3 | | 5-hydroxy-N,N-dimethyltryptamine;
|
4 | | N,N-dimethylserotonin; mappine); |
5 | | (31) (Blank); |
6 | | (32) (Blank); |
7 | | (33) (Blank); |
8 | | (34) (Blank); |
9 | | (34.5) (Blank); |
10 | | (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3- |
11 | | (2-methyloctan-2-yl)-6a,7, |
12 | | 10,10a-tetrahydrobenzo[c]chromen-1-ol |
13 | | Some trade or other names: HU-210; |
14 | | (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6- |
15 | | dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a- |
16 | | tetrahydrobenzo[c]chromen-1-ol, its isomers, |
17 | | salts, and salts of isomers; Some trade or other |
18 | | names: HU-210, Dexanabinol; |
19 | | (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)- |
20 | | 6,6-dimethyl-3-(2-methyloctan-2-yl)- |
21 | | 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol |
22 | | Some trade or other names: HU-211; |
23 | | (37) (Blank); |
24 | | (38) (Blank); |
25 | | (39) (Blank); |
26 | | (40) (Blank); |
|
| | SB1987 Enrolled | - 11 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (41) (Blank); |
2 | | (42) Any compound structurally derived from |
3 | | 3-(1-naphthoyl)indole or |
4 | | 1H-indol-3-yl-(1-naphthyl)methane by substitution at the |
5 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
6 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
7 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
8 | | 2-(4-morpholinyl)ethyl whether or not further substituted |
9 | | in the indole ring to any extent, whether or not |
10 | | substituted in the naphthyl ring to any extent. Examples |
11 | | of this structural class include, but are not limited to, |
12 | | JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185; |
13 | | (43) Any compound structurally derived from |
14 | | 3-(1-naphthoyl)pyrrole by substitution at the nitrogen |
15 | | atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, |
16 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
17 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
18 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
19 | | in the pyrrole ring to any extent, whether or not |
20 | | substituted in the naphthyl ring to any extent. Examples |
21 | | of this structural class include, but are not limited to, |
22 | | JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368; |
23 | | (44) Any compound structurally derived from |
24 | | 1-(1-naphthylmethyl)indene by substitution at the |
25 | | 3-position of the indene ring by alkyl, haloalkyl, |
26 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
|
| | SB1987 Enrolled | - 12 - | LRB103 25792 RLC 57149 b |
|
|
1 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
2 | | 2-(4-morpholinyl)ethyl whether or not further substituted |
3 | | in the indene ring to any extent, whether or not |
4 | | substituted in the naphthyl ring to any extent. Examples |
5 | | of this structural class include, but are not limited to, |
6 | | JWH-176; |
7 | | (45) Any compound structurally derived from |
8 | | 3-phenylacetylindole by substitution at the nitrogen atom |
9 | | of the indole ring with alkyl, haloalkyl, alkenyl, |
10 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
11 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
12 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
13 | | in the indole ring to any extent, whether or not |
14 | | substituted in the phenyl ring to any extent. Examples of |
15 | | this structural class include, but are not limited to, |
16 | | JWH-167, JWH-250, JWH-251, and RCS-8; |
17 | | (46) Any compound structurally derived from |
18 | | 2-(3-hydroxycyclohexyl)phenol by substitution at the |
19 | | 5-position of the phenolic ring by alkyl, haloalkyl, |
20 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
21 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
22 | | 2-(4-morpholinyl)ethyl, whether or not substituted in the |
23 | | cyclohexyl ring to any extent. Examples of this structural |
24 | | class include, but are not limited to, CP 47, 497 and its |
25 | | C8 homologue (cannabicyclohexanol); |
26 | | (46.1) Any compound structurally derived from |
|
| | SB1987 Enrolled | - 13 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 3-(benzoyl) indole with substitution at the nitrogen atom |
2 | | of the indole ring by an alkyl, haloalkyl, alkenyl, |
3 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
4 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
5 | | 2-(4-morpholinyl)ethyl group whether or not further |
6 | | substituted in the indole ring to any extent and whether |
7 | | or not substituted in the phenyl ring to any extent. |
8 | | Examples of this structural class include, but are not |
9 | | limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN |
10 | | 48,098), and RCS-4; |
11 | | (47) (Blank); |
12 | | (48) (Blank); |
13 | | (49) (Blank); |
14 | | (50) (Blank); |
15 | | (51) (Blank); |
16 | | (52) (Blank); |
17 | | (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine. |
18 | | Some trade or other names: 2C-T-7; |
19 | | (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some |
20 | | trade or other names: 2C-E; |
21 | | (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some |
22 | | trade or other names: 2C-D; |
23 | | (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some |
24 | | trade or other names: 2C-C; |
25 | | (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade |
26 | | or other names: 2C-I; |
|
| | SB1987 Enrolled | - 14 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some |
2 | | trade or other names: 2C-T-2; |
3 | | (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine. |
4 | | Some trade or other names: 2C-T-4; |
5 | | (53.7) 2,5-dimethoxyphenethylamine. Some trade or |
6 | | other names: 2C-H; |
7 | | (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some |
8 | | trade or other names: 2C-N; |
9 | | (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some |
10 | | trade or other names: 2C-P; |
11 | | (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine. |
12 | | Some trade or other names: 2C-G; |
13 | | (53.11) The N-(2-methoxybenzyl) derivative of any 2C |
14 | | phenethylamine referred to in subparagraphs (20.1), (53), |
15 | | (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7), |
16 | | (53.8), (53.9), and (53.10) including, but not limited to, |
17 | | 25I-NBOMe and 25C-NBOMe; |
18 | | (54) 5-Methoxy-N,N-diisopropyltryptamine; |
19 | | (55) (Blank); |
20 | | (56) (Blank); |
21 | | (57) (Blank); |
22 | | (58) (Blank); |
23 | | (59) 3-cyclopropoylindole with substitution at the |
24 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
25 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
26 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
|
| | SB1987 Enrolled | - 15 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
2 | | on the indole ring to any extent, whether or not |
3 | | substituted on the cyclopropyl ring to any extent: |
4 | | including, but not limited to, XLR11, UR144, FUB-144; |
5 | | (60) 3-adamantoylindole with substitution at the |
6 | | nitrogen atom of the indole ring by alkyl, haloalkyl, |
7 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
8 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
9 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
10 | | on the indole ring to any extent, whether or not |
11 | | substituted on the adamantyl ring to any extent: |
12 | | including, but not limited to, AB-001; |
13 | | (61) N-(adamantyl)-indole-3-carboxamide with |
14 | | substitution at the nitrogen atom of the indole ring by |
15 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
16 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
17 | | 1-(N-methyl-2-piperidinyl)methyl, or |
18 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
19 | | on the indole ring to any extent, whether or not |
20 | | substituted on the adamantyl ring to any extent: |
21 | | including, but not limited to, APICA/2NE-1, STS-135; |
22 | | (62) N-(adamantyl)-indazole-3-carboxamide with |
23 | | substitution at a nitrogen atom of the indazole ring by |
24 | | alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
25 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
26 | | 1-(N-methyl-2-piperidinyl)methyl, or |
|
| | SB1987 Enrolled | - 16 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
2 | | on the indazole ring to any extent, whether or not |
3 | | substituted on the adamantyl ring to any extent: |
4 | | including, but not limited to, AKB48, 5F-AKB48; |
5 | | (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester |
6 | | with substitution at the nitrogen atom of the indole ring |
7 | | by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, |
8 | | cycloalkylethyl, aryl halide, alkyl aryl halide, |
9 | | 1-(N-methyl-2-piperidinyl)methyl, or |
10 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
11 | | on the indole ring to any extent, whether or not |
12 | | substituted on the quinoline ring to any extent: |
13 | | including, but not limited to, PB22, 5F-PB22, FUB-PB-22; |
14 | | (64) 3-(1-naphthoyl)indazole with substitution at the |
15 | | nitrogen atom of the indazole ring by alkyl, haloalkyl, |
16 | | alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, |
17 | | alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or |
18 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
19 | | on the indazole ring to any extent, whether or not |
20 | | substituted on the naphthyl ring to any extent: including, |
21 | | but not limited to, THJ-018, THJ-2201; |
22 | | (65) 2-(1-naphthoyl)benzimidazole with substitution |
23 | | at the nitrogen atom of the benzimidazole ring by alkyl, |
24 | | haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
25 | | aryl halide, alkyl aryl halide, |
26 | | 1-(N-methyl-2-piperidinyl)methyl, or |
|
| | SB1987 Enrolled | - 17 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
2 | | on the benzimidazole ring to any extent, whether or not |
3 | | substituted on the naphthyl ring to any extent: including, |
4 | | but not limited to, FUBIMINA; |
5 | | (66) |
6 | | N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole- |
7 | | 3-carboxamide with substitution on the nitrogen atom of |
8 | | the indazole ring by alkyl, haloalkyl, alkenyl, |
9 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
10 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
11 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
12 | | on the indazole ring to any extent: including, but not |
13 | | limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA; |
14 | | (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
15 | | indazole-3-carboxamide with substitution on the nitrogen |
16 | | atom of the indazole ring by alkyl, haloalkyl, alkenyl, |
17 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
18 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
19 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
20 | | on the indazole ring to any extent: including, but not |
21 | | limited to, ADB-PINACA, ADB-FUBINACA; |
22 | | (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H- |
23 | | indole-3-carboxamide with substitution on the nitrogen |
24 | | atom of the indole ring by alkyl, haloalkyl, alkenyl, |
25 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
26 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
|
| | SB1987 Enrolled | - 18 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
2 | | on the indole ring to any extent: including, but not |
3 | | limited to, ADBICA, 5F-ADBICA; |
4 | | (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole- |
5 | | 3-carboxamide with substitution on the nitrogen atom of |
6 | | the indole ring by alkyl, haloalkyl, alkenyl, |
7 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
8 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
9 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
10 | | on the indole ring to any extent: including, but not |
11 | | limited to, ABICA, 5F-ABICA; |
12 | | (70) Methyl 2-(1H-indazole-3-carboxamido)-3- |
13 | | methylbutanoate with substitution on the nitrogen atom of |
14 | | the indazole ring by alkyl, haloalkyl, alkenyl, |
15 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl |
16 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
17 | | 2-(4-morpholinyl)ethyl, whether or not further substituted |
18 | | on the indazole ring to any extent: including, but not |
19 | | limited to, AMB, 5F-AMB; |
20 | | (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3- |
21 | | dimethylbutanoate with substitution on the nitrogen
atom |
22 | | of the indazole ring by alkyl, haloalkyl, alkenyl,
|
23 | | cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl
aryl |
24 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
25 | | 2-(4-morpholinyl)ethyl, whether or not further substituted
|
26 | | on the indazole ring to any extent: including, but not
|
|
| | SB1987 Enrolled | - 19 - | LRB103 25792 RLC 57149 b |
|
|
1 | | limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA; |
2 | | (72) Methyl 2-(1H-indole-3-carboxamido)-3- |
3 | | methylbutanoate with substitution on the nitrogen atom
of |
4 | | the indole ring by alkyl, haloalkyl, alkenyl,
|
5 | | cycloalkylmethyl, cycloalkylethyl, aryl halide,
alkyl aryl |
6 | | halide, 1-(N-methyl-2-piperidinyl)methyl,
or |
7 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted |
8 | | on the indazole ring to any extent:
including, but not |
9 | | limited to, MMB018, MMB2201,
and AMB-CHMICA; |
10 | | (73) Methyl 2-(1H-indole-3-carboxamido)-3,3- |
11 | | dimethylbutanoate with substitution
on the nitrogen atom |
12 | | of the indole ring by alkyl,
haloalkyl, alkenyl, |
13 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl |
14 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
15 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted |
16 | | on the
indazole ring to any extent: including, but
not |
17 | | limited to, MDMB-CHMICA; |
18 | | (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H- |
19 | | indazole-3-carboxamide with
substitution on the nitrogen |
20 | | atom of the indazole
ring by alkyl, haloalkyl, alkenyl, |
21 | | cycloalkylmethyl,
cycloalkylethyl, aryl halide, alkyl aryl |
22 | | halide,
1-(N-methyl-2-piperidinyl)methyl, or |
23 | | 2-(4-morpholinyl)ethyl, whether or not further
substituted |
24 | | on the indazole ring to any
extent: including, but not |
25 | | limited to, APP-CHMINACA,
5-fluoro-APP-PINACA; |
26 | | (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole- |
|
| | SB1987 Enrolled | - 20 - | LRB103 25792 RLC 57149 b |
|
|
1 | | 3-carboxamide with substitution on
the nitrogen atom of |
2 | | the indole ring by alkyl,
haloalkyl, alkenyl, |
3 | | cycloalkylmethyl, cycloalkylethyl,
aryl halide, alkyl aryl |
4 | | halide, 1-(N-methyl-2-piperidinyl)methyl, or |
5 | | 2-(4-morpholinyl)ethyl,
whether or not further substituted |
6 | | on the indazole
ring to any extent: including, but not |
7 | | limited to,
APP-PICA and 5-fluoro-APP-PICA; |
8 | | (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name |
9 | | 4-AcO-DMT; |
10 | | (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade |
11 | | name 5-MeO-MIPT; |
12 | | (78) 4-hydroxy Diethyltryptamine (4-HO-DET); |
13 | | (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET); |
14 | | (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT); |
15 | | (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
|
16 | | (4-HO-MiPT); |
17 | | (82) Fluorophenylpiperazine; |
18 | | (83) Methoxetamine; |
19 | | (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso- |
20 | | ethcathinone). |
21 | | (e) Unless specifically excepted or unless listed in |
22 | | another
schedule, any material, compound, mixture, or |
23 | | preparation which contains
any quantity of the following |
24 | | substances having a depressant effect on
the central nervous |
25 | | system, including its salts, isomers, and salts of
isomers |
26 | | whenever the existence of such salts, isomers, and salts of
|
|
| | SB1987 Enrolled | - 21 - | LRB103 25792 RLC 57149 b |
|
|
1 | | isomers is possible within the specific chemical designation: |
2 | | (1) mecloqualone; |
3 | | (2) methaqualone; and |
4 | | (3) gamma hydroxybutyric acid. |
5 | | (f) Unless specifically excepted or unless listed in |
6 | | another schedule,
any material, compound, mixture, or |
7 | | preparation which contains any quantity
of the following |
8 | | substances having a stimulant effect on the central nervous
|
9 | | system, including its salts, isomers, and salts of isomers: |
10 | | (1) Fenethylline; |
11 | | (2) N-ethylamphetamine; |
12 | | (3) Aminorex (some other names:
|
13 | | 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
|
14 | | 4-5-dihydro-5-phenyl-2-oxazolamine) and its
|
15 | | salts, optical isomers, and salts of optical isomers; |
16 | | (4) Methcathinone (some other names:
|
17 | | 2-methylamino-1-phenylpropan-1-one;
|
18 | | Ephedrone; 2-(methylamino)-propiophenone;
|
19 | | alpha-(methylamino)propiophenone; N-methylcathinone;
|
20 | | methycathinone; Monomethylpropion; UR 1431) and its
|
21 | | salts, optical isomers, and salts of optical isomers; |
22 | | (5) Cathinone (some trade or other names:
|
23 | | 2-aminopropiophenone; alpha-aminopropiophenone;
|
24 | | 2-amino-1-phenyl-propanone; norephedrone); |
25 | | (6) N,N-dimethylamphetamine (also known as:
|
26 | | N,N-alpha-trimethyl-benzeneethanamine;
|
|
| | SB1987 Enrolled | - 22 - | LRB103 25792 RLC 57149 b |
|
|
1 | | N,N-alpha-trimethylphenethylamine); |
2 | | (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
|
3 | | 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine); |
4 | | (8) 3,4-Methylenedioxypyrovalerone (MDPV); |
5 | | (9) Halogenated amphetamines and
|
6 | | methamphetamines - any compound derived from either
|
7 | | amphetamine or methamphetamine through the substitution
|
8 | | of a halogen on the phenyl ring, including, but not
|
9 | | limited to, 2-fluoroamphetamine, 3-
|
10 | | fluoroamphetamine and 4-fluoroamphetamine; |
11 | | (10) Aminopropylbenzofuran (APB):
|
12 | | including 4-(2-Aminopropyl) benzofuran, 5-
|
13 | | (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
|
14 | | benzofuran, and 7-(2-Aminopropyl) benzofuran; |
15 | | (11) Aminopropyldihydrobenzofuran (APDB):
|
16 | | including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
|
17 | | 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
|
18 | | 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
|
19 | | and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran; |
20 | | (12) Methylaminopropylbenzofuran
|
21 | | (MAPB): including 4-(2-methylaminopropyl)
|
22 | | benzofuran, 5-(2-methylaminopropyl)benzofuran,
|
23 | | 6-(2-methylaminopropyl)benzofuran
|
24 | | and 7-(2-methylaminopropyl)benzofuran. |
25 | | (g) Temporary listing of substances subject to emergency |
26 | | scheduling.
Any material, compound, mixture, or preparation |
|
| | SB1987 Enrolled | - 23 - | LRB103 25792 RLC 57149 b |
|
|
1 | | that contains any quantity
of the following substances: |
2 | | (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
|
3 | | (benzylfentanyl), its optical isomers, isomers, salts,
and |
4 | | salts of isomers; |
5 | | (2) N-[1(2-thienyl)
methyl-4-piperidyl]-N- |
6 | | phenylpropanamide (thenylfentanyl),
its optical isomers, |
7 | | salts, and salts of isomers. |
8 | | (h) Synthetic cathinones. Unless specifically excepted, |
9 | | any chemical compound which is not approved by the United |
10 | | States Food and Drug Administration or, if approved, is not |
11 | | dispensed or possessed in accordance with State or federal |
12 | | law, not including bupropion, structurally derived from |
13 | | 2-aminopropan-1-one by substitution at the 1-position with |
14 | | either phenyl, naphthyl, or thiophene ring systems, whether or |
15 | | not the compound is further modified in one or more of the |
16 | | following ways: |
17 | | (1) by substitution in the ring system to any extent |
18 | | with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or |
19 | | halide substituents, whether or not further substituted in |
20 | | the ring system by one or more other univalent |
21 | | substituents. Examples of this class include, but are not |
22 | | limited to, 3,4-Methylenedioxycathinone (bk-MDA); |
23 | | (2) by substitution at the 3-position with an acyclic |
24 | | alkyl substituent. Examples of this class include, but are |
25 | | not limited to, 2-methylamino-1-phenylbutan-1-one |
26 | | (buphedrone); or |
|
| | SB1987 Enrolled | - 24 - | LRB103 25792 RLC 57149 b |
|
|
1 | | (3) by substitution at the 2-amino nitrogen atom with |
2 | | alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by |
3 | | inclusion of the 2-amino nitrogen atom in a cyclic |
4 | | structure. Examples of this class include, but are not |
5 | | limited to, Dimethylcathinone, Ethcathinone, and |
6 | | a-Pyrrolidinopropiophenone (a-PPP); or |
7 | | Any other synthetic cathinone which is not approved by the |
8 | | United States Food and Drug Administration or, if approved, is |
9 | | not dispensed or possessed in accordance with State or federal |
10 | | law. |
11 | | (i) Synthetic cannabinoids or piperazines. Any synthetic |
12 | | cannabinoid or piperazine which is not approved by the United |
13 | | States Food and Drug Administration or, if approved, which is |
14 | | not dispensed or possessed in accordance with State and |
15 | | federal law. |
16 | | (j) Unless specifically excepted or listed in another |
17 | | schedule, any chemical compound which is not approved by the |
18 | | United States Food and Drug Administration or, if approved, is |
19 | | not dispensed or possessed in accordance with State or federal |
20 | | law, and is derived from the following structural classes and |
21 | | their salts: |
22 | | (1) Benzodiazepine class: A fused 1,4-diazepine and |
23 | | benzene ring structure with a phenyl connected to the |
24 | | 1,4-diazepine ring, with any substitution(s) or |
25 | | replacement(s) on the 1,4-diazepine or benzene ring, any |
26 | | substitution(s) on the phenyl ring, or any combination |
|
| | SB1987 Enrolled | - 25 - | LRB103 25792 RLC 57149 b |
|
|
1 | | thereof. Examples of this class include but are not |
2 | | limited to: Clonazolam, Flualprazolam; or |
3 | | (2) Thienodiazepine class: A fused 1,4-diazepine and |
4 | | thiophene ring structure with a phenyl connected to the |
5 | | 1,4-diazepine ring, with any substitution(s) or |
6 | | replacement(s) on the 1,4-diazepine or thiophene ring, any |
7 | | substitution(s) on the phenyl ring, or any combination |
8 | | thereof. Examples of this class include but are not |
9 | | limited to: Etizolam. |
10 | | (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17; |
11 | | 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff. |
12 | | 8-14-18 .)
|